NHS and licensed weight-loss options in the UK

There is a legal, regulated route to weight-loss help in the UK, and it includes two licensed injections and, since August 2026, a licensed tablet. It starts with your GP. Retatrutide is not on it, and cannot be, because no regulator has approved it.

The NICE pathway in plain English

NICE guideline NG246, updated in January 2025, is the rulebook the NHS in England uses for overweight and obesity.^[1] Traditionally the services are described in tiers:

• Tier 1: public health and self-help: information, apps, free programmes.
• Tier 2: community lifestyle programmes: group sessions on diet and activity, often 12 weeks, run by councils or the NHS.
• Tier 3: specialist weight-management services with a team that usually includes a doctor, dietitian, psychologist and physiotherapist. This is where most licensed medicines are prescribed.
• Tier 4: bariatric surgery, with specialist support before and after.

NICE's newer guidance uses less of the tier language and more of "levels of support", but the NHS and NICE technology appraisals still refer to tiers 3 and 4 when they describe where medicines can be prescribed.^[4] What matters for you is that the route into all of it is the same: a GP or practice nurse assessment.

Free NHS programmes

NHS Digital Weight Management Programme. A 12-week online behaviour and lifestyle programme, accessed by phone or computer, for adults living with obesity who also have diabetes, high blood pressure or both. Referral is through a GP or a health professional.^[2]

Better Health. The NHS's free, self-directed weight-loss plan, with a 12-week app, meal ideas and activity plans, open to anyone.^[3] It pairs well with the protein and training pages on this site.

Local services. Most areas have a council or NHS tier 2 programme; the NHS obesity treatment page explains how to find yours.^[10]

Wegovy (semaglutide): who qualifies

NICE technology appraisal TA875 recommends semaglutide (Wegovy) for weight management only if it is used for a maximum of two years, within a specialist weight-management service, and the person has at least one weight-related condition and either a BMI of 35 or more, or a BMI of 30 to 34.9 and meets the criteria for referral to a specialist service.^[4] Lower BMI thresholds apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds.^[4]

Mounjaro (tirzepatide): who qualifies, and the phased rollout

NICE technology appraisal TA1026 recommends tirzepatide (Mounjaro) for adults with a BMI of at least 35 and at least one weight-related condition, alongside a reduced-calorie diet and increased activity. It can be prescribed in primary care as well as specialist services. The BMI thresholds are reduced by 2.5 for people from the ethnic backgrounds listed above.^[5]

Because the eligible population is very large, NHS England asked NICE to allow a phased rollout, and the result is a plan that reaches the full eligible population over a maximum of 12 years.^[11] In the first three years, from 2025 to 2028, access in GP practices is being opened in stages to about 220,000 people with the highest clinical need, defined by BMI and the number of weight-related conditions such as high blood pressure, abnormal blood fats, sleep apnoea, heart disease and type 2 diabetes. NICE will review the rollout after the first three years.^[6] The practical meaning: you may meet the NICE criteria and still not be eligible on the NHS yet. Your GP can tell you which stage you fall into.

Orforglipron (Foundayo): the tablet

Orforglipron is a once-daily GLP-1 tablet, also from Lilly. The MHRA authorised it for weight management and type 2 diabetes on 10 August 2026, the first regulator in Europe to do so.^[7] NICE is appraising it for the NHS, with publication expected on 18 November 2026.^[8] Until then it is licensed but not NHS-funded; private prescribing may follow the same regulated route as the injections.

Private prescribing: the regulated route

Wegovy and Mounjaro can be prescribed privately, and the NHS's own tirzepatide page acknowledges this while warning people to check they are dealing with a legitimate provider.^[12] In outline, the legal route involves:

• a registered prescriber (a doctor, or a pharmacist or nurse with prescribing qualifications) who takes a history, checks your BMI and weight-related conditions, and decides whether the medicine is appropriate;
• a pharmacy registered with the General Pharmaceutical Council (GPhC), which is the only kind that can lawfully dispense a prescription-only medicine in Great Britain, and which will ask for identification and medical information;
• the licensed product in its licensed pen, with a patient information leaflet and a batch number;
• follow-up, because the licence requires the medicine to be used alongside diet and activity support and monitored.

The MHRA's #FakeMeds campaign explains how to check that an online pharmacy is registered.^[13] Anything that skips the consultation, sells vials rather than pens, calls the product "research use only" or ships from an unnamed overseas address is not on this route. This site does not recommend providers; the point is that the legal route has specific, checkable features and that products sold as retatrutide have none of them. See is it legal in the UK?

How to get assessed

1. Work out your BMI. The NHS classes a BMI of 25 to 29.9 as overweight and 30 or more as obese. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the thresholds are 23 and 27.5, because health risks rise at a lower BMI.^[14] Waist measurement matters too: the NHS suggests keeping your waist to less than half your height.^[14]
2. Book a GP or practice nurse appointment and say you want help with your weight. Take a list of any conditions you have and medicines you take.
3. Be honest about anything you have already used, including unlicensed products. Your GP is not there to judge you and cannot assess you properly without knowing. Talking to your GP covers this.
4. Ask what you are eligible for now, and what the waiting times are. Specialist services in some areas have long waits; the free programmes and this site's weight-loss advice are worth starting in the meantime.

Where retatrutide fits

It does not, yet. Retatrutide has no marketing authorisation from the MHRA, the FDA or the EMA. It cannot be prescribed on the NHS or privately, a GPhC-registered pharmacy cannot dispense it, and the MHRA has said that products sold in the UK claiming to contain it are likely to be illegal and potentially dangerous.^[9] Lilly has said it plans to file for US approval in early 2027; a UK licence and an NHS decision would come after that. What is retatrutide? has the timeline. Until then, the options on this page are the options.